Light, chemistry, action -- a new technique to target skin cancers?

Targeted photodynamic therapy can completely eradicate some models of cancer, according to the latest research by UK and Swiss scientists, published in the current issue of the British Journal of Cancer.

The team – including researchers from the University of Hull and ETH Zurich – linked light-sensitive with antibodies that target tumour . When irradiated with light, the molecules create particles known as reactive oxygen species, which in high numbers cause irreparable damage to cells.

By ensuring the light-sensitive molecules were targeted at the tumour blood vessels, the researchers could starve the tumour of oxygen and nutrients and cause it to disappear completely, with no re-growth during the following 100 days.

"There are already drugs in clinical use which target tumour blood vessels, but these only inhibit growth rather than completely kill the tumour," explains Dr Ross Boyle, from Hull's Department of Chemistry, who designs and creates the light-sensitive molecules used in the research.

"By using this form of targeted photodynamic therapy, we were able to completely kill the tumour in our models. Though this is still a long way from being used on patients, it does hold exciting potential for the treatments of some of the most common skin cancers."

However, the tumour was only completely eradicated when 'natural killer cells' – a key part of the immune system – were present. When the production of these was blocked, the tumour reduced in size, but did not disappear. The team believe further research is needed to determine the exact role of the immune system in the process.

Targeting light-sensitive molecules to a tumour site ensures that the treatment should be more effective even at smaller doses, improving outcomes and reducing potential side effects to patients. The technique could potentially replace more invasive forms of treatment such as surgery and radiotherapy.

Dr Boyle and his colleagues are now applying for further funding to move the research closer to clinical trials.

Related Stories

New targeted approach to light-activated cancer drugs

date Nov 08, 2007

Combining light-activated cancer drugs with tumour-seeking antibodies could provide a more effective way of treating many cancers, according to new research published in advance online in the International Journal of Cancer.

Innovative method to starve tumors

date Feb 11, 2009

The development of cancerous tumours is highly dependent on the nutrients the tumours receive through the blood. The team of Dr. Janusz Rak, of the Research Institute of the McGill University Health Centre (MUHC) at the Montreal ...

Recommended for you

Study finds new potential melanoma drug target

date May 02, 2015

A new treatment for melanoma could be on the horizon, thanks to a finding by a UNC Lineberger Comprehensive Cancer Center-led team. In the study, which was published online today in the journal Clinical Ca ...

Surgery for terminal cancer patients still common

date May 02, 2015

The number of surgeries performed on terminally ill cancer patients has not dropped in recent years, despite more attention to the importance of less invasive care for these patients to relieve symptoms and ...

Study provides comprehensive look at brain cancer treatments

date May 01, 2015

Led by the Translational Genomics Research Institute (TGen) and UC San Francisco (UCSF), a comprehensive genetic review of treatment strategies for glioblastoma brain tumors was published today in the Oxford University Press ...

How artificial tanning can lead to melanoma

date May 01, 2015

Young women may be up on the latest fashions and trends as they prepare for prom season. But what many don't know is that the tan that looks oh-so-good with their dress may be the first step toward skin cancer.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.